(Boursier.com) — Lysogen a phase 3 biopharmaceutical company based on a gene therapy technology platform targeting central nervous system (CNS) diseases, announces that the Commercial Court of Nanterre has decided to convert the company’s receivership proceedings, opened by judgment of January 24, 2023, in judicial liquidation proceedings.
Given the opening of this judicial liquidation procedure, there will be no resumption of the trading of Lysogene shares and a request will soon be made to Euronext for the delisting of Lysogene shares.
©2023 Boursier.com